Hemostemix (HEM) AI Stock Analysis

• Market Cap: C$16.02M
• Dividend Yield: N/A
• Average Volume (3M): 138.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.11
• Revenue Growth: N/A
• EPS Growth: -24.89%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 188,488,540
• 10 Day Avg. Volume: 155,944
• 30 Day Avg. Volume: 138,348
• PEG Ratio: 0.47
• Price to Book (P/B): -1.58
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.08 ▲(1.25% Upside)

The score is primarily held down by very weak financial performance (no revenue, persistent losses, negative equity, and a sharp increase in recent cash burn), implying high reliance on external funding. Technicals are also weak-to-neutral with negative MACD and the price below key longer-term moving averages. Corporate events provide some support via incremental financing and product visibility, but not enough to offset the balance-sheet and cash-flow risks.

Positive Factors

Funding for Product Development

The recent funding will enhance Hemostemix's ability to advance its stem cell therapeutics platform, supporting long-term product development and commercialization efforts.

Commitment to Innovation

Investment in ACP processing underscores Hemostemix's commitment to innovation, which is crucial for long-term success in the competitive biotechnology industry.

Strategic Focus on Stem Cell Therapies

Hemostemix's focus on stem cell therapies positions it well in the regenerative medicine field, addressing unmet medical needs and potentially capturing significant market share.

Negative Factors

Lack of Revenue Generation

The absence of revenue generation highlights significant challenges in achieving profitability, necessitating strategic realignment for financial sustainability.

Cash Flow Challenges

Negative cash flows suggest reliance on external financing, which can strain resources and hinder strategic initiatives if not addressed.

Financial Instability

High leverage and negative equity indicate financial instability, limiting Hemostemix's ability to invest in growth and posing risks to long-term sustainability.

Hemostemix Business Overview & Revenue Model

Company Description

Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

How the Company Makes Money

Hemostemix makes money primarily through the development, licensing, and commercialization of its stem cell therapies. Its key revenue streams include potential licensing agreements with pharmaceutical companies, research grants, and partnerships for co-development of its therapies. Additionally, the company may generate income from milestone payments and royalties upon successful commercialization of its treatments. Hemostemix also explores opportunities for strategic collaborations to enhance its product pipeline and expand its market reach. However, as a biotechnology company in the pre-commercialization stage, it may not yet have significant revenue streams from product sales.

Hemostemix Financial Statement Overview

Summary

Hemostemix's financial health is precarious, with no revenue generation, significant losses, high leverage, and poor cash flow management. The company faces substantial financial distress, highlighting a need for strategic operational improvements and potential funding solutions.

Income Statement

Hemostemix has struggled with consistent revenue generation, as evidenced by zero revenue over the years. The company faces significant profitability challenges, with consistently negative net income and EBIT margins. There is no revenue growth, and high operating losses persist, indicating a need for strategic realignment to achieve financial sustainability.

Balance Sheet

The company's balance sheet highlights a concerning leverage situation with negative stockholder equity and a very high debt-to-equity ratio, indicating financial instability. The lack of equity and substantial liabilities present risks and limit financial flexibility. Total assets have decreased over time, exacerbating the leverage issue.

Cash Flow

Hemostemix faces significant cash flow challenges, with consistent negative operating and free cash flows, indicating reliance on external financing to maintain operations. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in cash generation relative to earnings. The company needs to improve its cash flow management to avoid liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-60.00	-100.00	-223.00	-495.00	-1.10K	-2.45K
EBITDA	-3.40M	-1.98M	-1.95M	-4.39M	-6.45M	-7.65M
Net Income	-4.39M	-2.62M	-2.50M	-5.24M	-6.29M	-7.77M
Balance Sheet
Total Assets	1.34M	991.86K	313.76K	465.35K	563.05K	2.32M
Cash, Cash Equivalents and Short-Term Investments	1.30M	705.70K	155.42K	135.75K	219.44K	257.95K
Total Debt	3.44M	4.94M	4.32M	4.13M	1.48M	175.00K
Total Liabilities	4.80M	8.20M	7.68M	7.23M	5.85M	3.42M
Stockholders Equity	-3.46M	-7.20M	-7.37M	-6.77M	-5.28M	-1.10M
Cash Flow
Free Cash Flow	-5.18M	-1.90M	-1.42M	-6.10M	-3.48M	-5.98M
Operating Cash Flow	-5.18M	-1.90M	-1.42M	-6.10M	-3.48M	-5.98M
Investing Cash Flow	-145.58K	0.00	0.00	0.00	171.12K	0.00
Financing Cash Flow	6.42M	2.45M	1.44M	6.02M	3.27M	6.21M

Hemostemix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEM, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.65 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HEM.

Hemostemix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLAB	47 Neutral	C$12.98M	-1.60	―	―	-3.93%	-575.24%
PREV	42 Neutral	C$14.67M	-4.55	21.59%	―	―	-120.00%
HEM	41 Neutral	C$16.02M	-2.85	―	―	―	-24.89%
GLAB	41 Neutral	C$4.59M	-1.54	―	―	―	9.06%

Hemostemix Corporate Events

Hemostemix Raises C$480,000 to Advance Stem Cell Therapy Commercialization

Hemostemix has raised C$480,000 through a non-brokered private placement of 4,000,000 common shares priced at C$0.12 each, with the financing subject to final approval from the TSX Venture Exchange and subject to a statutory hold period under securities laws. The company intends to use the proceeds to fund general working capital and to advance regulatory, clinical and commercialization efforts for its ACP-01 (VesCell) autologous angiogenic cell therapy platform, supporting its push toward broader market adoption in ischemia-related indications and reinforcing its capital base for ongoing development initiatives.

The most recent analyst rating on (TSE:HEM) stock is a Hold with a C$0.08 price target. To see the full list of analyst forecasts on Hemostemix stock, see the TSE:HEM Stock Forecast page.

Hemostemix Grants Stock Options to Boost Growth

Hemostemix Inc. announced the granting of 963,000 stock options to its directors, officers, employees, and consultants as part of its stock option plan. The options, which have an exercise price of $0.09 per share and expire in 2030, aim to align the interests of the company’s leadership with its growth objectives. This move reflects Hemostemix’s commitment to advancing its position in the stem cell therapy industry and could potentially enhance stakeholder confidence.

Hemostemix Highlights VesCell Success at DFCon 2025 and Secures New Funding

Hemostemix announced its participation in DFCon 2025, a leading conference on diabetic foot care, where it will showcase its stem cell therapy, VesCell, which has shown promising results in reducing mortality and preserving limbs in diabetic patients. Additionally, Hemostemix closed a non-brokered private placement of $518,440, which will support its ongoing operations and potentially enhance its market position in the stem cell therapy industry.

Hemostemix Secures CDN$280,594 Private Placement for Operational Growth

Hemostemix Inc. announced the conditional approval of its CDN$280,594 private placement by the TSX Venture Exchange, involving the issuance of 2,244,752 common shares. The funds will be used for general working capital, supporting operational expenses and business development. This move is expected to bolster Hemostemix’s financial position, aiding in the continued development and commercialization of its stem cell therapies, potentially enhancing its market presence and stakeholder value.

Hemostemix Closes $461,230 Private Placement to Boost Operations

Hemostemix Inc. announced the closing of its first tranche of a non-brokered private placement, raising $461,230 through the issuance of 4,193,000 units. Each unit consists of a common share and a warrant, with proceeds intended for general working capital and the marketing and sales of VesCell, its proprietary stem cell therapy. The offering involved related party transactions and is subject to regulatory approvals, with securities issued subject to a four-month hold period under Canadian securities laws.